Geron Analyst Ratings
Buy Rating Affirmed for Geron's Rytelo on Strong Launch and Positive Clinical Outlook
Geron Analyst Ratings
Stifel Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $7
Stifel Nicolaus Reaffirms Their Buy Rating on Geron (GERN)
Goldman Sachs Maintains Geron(GERN.US) With Buy Rating
Goldman Sachs Keeps Their Buy Rating on Geron (GERN)
Geron Analyst Ratings
Critical Insights From Geron Analyst Ratings: What You Need To Know
Geron Analyst Ratings
Wedbush Raises Geron's Price Target to $8 From $7, Outperform Rating Maintained
Geron Analyst Ratings
Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating
Geron Analyst Ratings
Buy Rating Affirmed for Geron Amid Positive Imetelstat Launch Prospects and Strong Financials
Analysts Conflicted on These Healthcare Names: Dyne Therapeutics (DYN) and Geron (GERN)
Geron Analyst Ratings
Geron Analyst Ratings
Buy Rating Affirmed for Geron Following Insightful Leadership Discussion and Promising Drug Development Progress
Analysts Offer Insights on Healthcare Companies: Carl Zeiss Meditec (GB:0DHC), Geron (GERN) and Zur Rose Group AG (Six Swiss: CH:DOCM)